Study guide

15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy

NCRA Oncology Data Specialist ODS-C

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters

1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish

2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws

2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority

3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance

3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance

4 Chapter 4: Registry Organization, Staffing & Information Systems

4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning

5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement

5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)

6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality

6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)

7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics

7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data

8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer

8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors

9 Chapter 9: Casefinding & Reportability

9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"

10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators

10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More

11 Chapter 11: Class of Case, Key Dates & Case Identifiers

11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them

12 Chapter 12: Follow-Up, Vital Status & Recurrence

12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary

13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade

13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables

14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules

14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules

15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018

15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples

16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS

16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation

15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy

Key Takeaways Explain This Topic AI

Clinical classification uses information from diagnosis until the start of treatment or a decision for watchful waiting or supportive care, or four months after diagnosis, whichever is shorter, as long as the cancer has not clearly progressed.

Pathological classification adds surgical findings through completion of definitive surgery or four months after diagnosis, whichever is longer, provided no systemic or radiation therapy was given first and the cancer has not clearly progressed.

After neoadjuvant therapy, the case keeps its clinical classification, gets yc if sampled after treatment and yp from the resection, and the pathological (p) classification does not apply.

Metastasis or progression discovered after the time frame ends is not added to the stage; findings in the time frame, including those from other facilities, are.

Recurrence (r) staging does not replace the original stage, and autopsy (a) staging is used only when cancer is first found at autopsy.

Last updated: September 2026

The clinical classification (cTNM)

Sources: physical examination, imaging, endoscopy, laboratory tests, biopsy (including sentinel node biopsy for some sites), and surgical exploration without resection.

Time frame: from diagnosis until the start of treatment (or a decision for watchful waiting or supportive care) or four months after diagnosis, whichever is shorter , as long as the cancer has not clearly progressed.

Key points:

Every analytic case (Class of Case 10–22) gets a clinical classification, even if surgery comes first.

A biopsy of the primary in the clinical time frame is still clinical information.

Microscopically confirmed distant metastasis found during clinical staging is recorded as pM1 within the clinical classification, and it makes the clinical stage group IV .

Nodes are cN unless microscopically assessed. Some chapters allow cN1(f) after a positive FNA or core biopsy of a node.

The pathological classification (pTNM)

Sources: everything in the clinical classification plus findings from the surgical resection and pathology.

Time frame: through completion of definitive surgery in the first course of treatment, or four months after diagnosis, whichever is longer , as long as:

no systemic or radiation therapy was given before the surgery, and

the cancer has not clearly progressed .

Requirements:

The resection must meet the chapter's criteria for pT. As Section 15.1 explains, microscopic confirmation of the highest T or N category can also be enough.

If the primary is not resected, pathological T is usually not assigned. The exception is proof of the highest category or pM1.

Clinical information carries forward. For example, a distant metastasis seen only on imaging (cM1) remains part of the pathological stage.

Post-therapy classifications (yc and yp)

Neoadjuvant therapy means systemic, radiation, or combined therapy given before planned surgery, for a guideline-supported reason.

  • Classification When Notes
  • cTNM Before neoadjuvant therapy Still required; it records the pre-treatment extent

ycTNM After neoadjuvant therapy or primary systemic or radiation therapy, from clinical assessment or biopsy, before surgery STORE items start at 1062 (2021+)

ypTNM Resection after neoadjuvant therapy Measures response. For example, ypT0 ypN0 is a pathologic complete response

pTNM Not assigned , because the pathological criteria (surgery without prior therapy) are not met Code 88 is not used for this; STORE reserves 88 for tumors AJCC does not stage

More post-therapy rules:

M is carried from the pre-treatment classification. A patient who had M1 before neoadjuvant therapy stays M1, so stage IV for most sites, even if the metastasis disappears.

ypT is based on the residual invasive tumor . Treatment-related fibrosis is not counted as tumor. Each chapter explains how to measure residual disease.

If therapy was given for unconventional reasons (for example, the patient's preference not supported by guidelines), the case may not qualify for y classification. Follow the chapter guidance.

Progression and time frame boundaries

Clearly progressed disease during the time frame ends that classification. Findings after that point are not used.

A metastasis discovered after the time frame is not added to the original stage. It is follow-up information (recurrence or progression).

Findings from other facilities within the time frame are used. Stage is based on all available information, not only your facility's records.

Recurrence (r) and autopsy (a)

rTNM stages a recurrence or retreatment. Registries do not replace the original stage with it.

aTNM applies when the cancer is first found at autopsy . If cancer was diagnosed during life and the patient died during the pathological time frame, autopsy findings can contribute to that classification. For example, the Grade Manual's autopsy examples follow the same logic.

Worked cases

Scenario Classifications to record

Breast cancer: imaging and core biopsy, then lumpectomy with sentinel nodes, no neoadjuvant therapy cTNM from the workup; pTNM from the lumpectomy plus clinical data; yc and yp blank

Rectal cancer: MRI cT3 cN1 cM0, then chemoradiation, then low anterior resection showing ypT2 ypN0 cT3 cN1 cM0 (clinical); ypT2 ypN0 cM0 (post-therapy); pTNM not assigned

Prostate cancer: biopsy, then active surveillance cTNM only; pathological classification not assigned

Lung cancer: biopsy-proven adrenal metastasis at diagnosis, palliative chemotherapy Clinical includes pM1b , stage IV. Pathological stage IV is also allowed because metastasis was microscopically confirmed

Colon cancer resected in March, liver metastasis first found in September The September finding is outside the time frame, so it is not added. Record it as recurrence or progression

Time frame summary

  • Classification Ends
  • Clinical Start of treatment, or four months after diagnosis, whichever is shorter

Pathological End of definitive surgery, or four months after diagnosis, whichever is longer (no neoadjuvant therapy)

Summary Stage 2018 Four months after diagnosis, or completion of first-course surgery, whichever is longer (Section 15.6)

Loading diagram... Which classifications apply?